These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 30350297)

  • 1. Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
    Valade E; Valenzuela B; Kakuda TN; Westland C; McClure MW; Ouwerkerk-Mahadevan S; Perez-Ruixo JJ; Ackaert O
    AAPS J; 2018 Oct; 20(6):111. PubMed ID: 30350297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.
    Valade E; Kakuda TN; McClure MW; Westland C; Valenzuela B; Ouwerkerk-Mahadevan S; Perez-Ruixo JJ; Ackaert O
    AAPS J; 2018 Oct; 21(1):1. PubMed ID: 30377854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
    Kakuda TN; McClure MW; Westland C; Vuong J; Homery MC; Poizat G; Viguerie L; Denot C; Patat A; Zhang Q; Hui J; Apelian D; Smith DB; Chanda SM; Fry J
    Pharmacol Res Perspect; 2018 Jun; 6(3):e00395. PubMed ID: 29736243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Gane EJ; Stedman CA; Schwabe C; Vijgen L; Chanda S; Kakuda TN; Fry J; Blatt LM; McClure MW
    Hepatology; 2018 Dec; 68(6):2145-2157. PubMed ID: 30070722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
    Bourgeois S; Horsmans Y; Nevens F; van Vlierberghe H; Moreno C; Beumont M; Vijgen L; van Eygen V; Luo D; Hillewaert V; Van Remoortere P; van de Logt J; Ouwerkerk-Mahadevan S
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
    Nakayama S; Toshimoto K; Yamazaki S; Snoeys J; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1461-1472. PubMed ID: 37667529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.
    Rajagopalan R; Pan L; Schaefer C; Nicholas J; Lim S; Misialek S; Stevens S; Hooi L; Aleskovski N; Ruhrmund D; Kossen K; Huang L; Yap S; Beigelman L; Serebryany V; Liu J; Sastry S; Seiwert S; Buckman B
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
    Marra F; Höner Zu Siederdissen C; Khoo S; Back D; Schlag M; Ouwerkerk-Mahadevan S; Bicer C; Lonjon-Domanec I; Jessner W; Beumont-Mauviel M; Kalmeijer R; Cornberg M
    Br J Clin Pharmacol; 2018 May; 84(5):961-971. PubMed ID: 29345798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.
    Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
    Clin Pharmacokinet; 2017 Jul; 56(7):781-792. PubMed ID: 27896690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment.
    Ouwerkerk-Mahadevan S; Beumont-Mauviel M; Mortier S; Peeters M; Verloes R; Truyers C; Mannens G; Wynant I; Simion A
    Drugs R D; 2015 Sep; 15(3):261-70. PubMed ID: 26248593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
    Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
    J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
    J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
    Bourgeois S; Van Vlierberghe H; Moreno C; Orlent H; Nevens F; Arastéh K; Horsmans Y; Schattenberg JM; Buggisch P; Francque S; Vijgen L; Kakuda TN; Hoeben E; Luo D; Vandebosch A; Jacquemyn B; Van Remoortere P; Verloes R
    BMC Gastroenterol; 2017 Feb; 17(1):26. PubMed ID: 28187751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir: a macrocyclic HCV protease inhibitor.
    Talwani R; Heil EL; Gilliam BL; Temesgen Z
    Drugs Today (Barc); 2013 Dec; 49(12):769-79. PubMed ID: 24524095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.
    Bhamidimarri KR; Czul F; Peyton A; Levy C; Hernandez M; Jeffers L; Roth D; Schiff E; O'Brien C; Martin P
    J Hepatol; 2015 Sep; 63(3):763-5. PubMed ID: 26095179
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
    Ouwerkerk-Mahadevan S; Snoeys J; Peeters M; Beumont-Mauviel M; Simion A
    Clin Pharmacokinet; 2016 Feb; 55(2):197-208. PubMed ID: 26353895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.
    Boglione L; De Nicolò A; Mornese Pinna S; Cusato J; Favata F; Ariaudo A; Carcieri C; Cariti G; Di Perri G; D'Avolio A
    Dig Liver Dis; 2017 Jun; 49(6):705-708. PubMed ID: 28174003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.